DK2606069T3 - Humaniserede antistoffer mod alfakæden af anti-interleukin-3-receptoren - Google Patents
Humaniserede antistoffer mod alfakæden af anti-interleukin-3-receptorenInfo
- Publication number
- DK2606069T3 DK2606069T3 DK11817577.7T DK11817577T DK2606069T3 DK 2606069 T3 DK2606069 T3 DK 2606069T3 DK 11817577 T DK11817577 T DK 11817577T DK 2606069 T3 DK2606069 T3 DK 2606069T3
- Authority
- DK
- Denmark
- Prior art keywords
- interleukin
- receptor
- antibodies against
- humanized antibodies
- alpha chain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Physics & Mathematics (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37448910P | 2010-08-17 | 2010-08-17 | |
PCT/AU2011/000155 WO2011100786A1 (en) | 2010-02-17 | 2011-02-17 | Compositions and methods for targeting type 1 interferon producing cells |
PCT/AU2011/001056 WO2012021934A1 (en) | 2010-08-17 | 2011-08-17 | Humanized anti-interleukin 3 receptor alpha chain antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2606069T3 true DK2606069T3 (da) | 2014-09-08 |
Family
ID=45604615
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK11817577.7T DK2606069T3 (da) | 2010-08-17 | 2011-08-17 | Humaniserede antistoffer mod alfakæden af anti-interleukin-3-receptoren |
Country Status (13)
Country | Link |
---|---|
US (3) | US8569461B2 (da) |
EP (2) | EP2778175B1 (da) |
JP (2) | JP5524418B2 (da) |
KR (1) | KR101347688B1 (da) |
CN (1) | CN103025761B (da) |
CA (1) | CA2805176C (da) |
DK (1) | DK2606069T3 (da) |
ES (1) | ES2506340T3 (da) |
GB (1) | GB2488091B (da) |
IL (1) | IL225631A (da) |
NZ (1) | NZ604510A (da) |
PL (1) | PL2606069T3 (da) |
WO (1) | WO2012021934A1 (da) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2009270181B2 (en) * | 2008-07-10 | 2014-05-29 | Toray Industries, Inc. | Pharmaceutical composition for treatment and prevention of cancer |
US20100209341A1 (en) | 2009-02-18 | 2010-08-19 | Csl Limited | Treatment of chronic inflammatory conditions |
CA2764432C (en) | 2009-04-27 | 2017-10-24 | Kyowa Hakko Kirin Co., Ltd. | Interleukin-3 receptor alpha chain-binding antibody to treat leukemia |
NZ604510A (en) | 2010-08-17 | 2013-10-25 | Csl Ltd | Dilutable biocidal compositions and methods of use |
ES2924722T3 (es) * | 2012-05-18 | 2022-10-10 | Aptevo Res & Development Llc | Unión de inmunofusión de scFv biespecífico (BIf) a CD123 y CD3 |
US20160046718A1 (en) * | 2013-03-14 | 2016-02-18 | Csl Limited | Agents that neutralize il-3 signalling and uses thereof |
WO2014138805A1 (en) * | 2013-03-14 | 2014-09-18 | Csl Limited | Anti il-3r alpha agents and uses thereof |
EP2839842A1 (en) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof |
MA53145A (fr) * | 2014-09-05 | 2021-05-19 | Janssen Pharmaceutica Nv | Agents de liaison cd123 et leurs utilisations |
EP3247725B1 (en) * | 2015-01-23 | 2020-07-01 | Sanofi | Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123 |
TW201709932A (zh) * | 2015-06-12 | 2017-03-16 | 西雅圖遺傳學公司 | Cd123抗體及其共軛物 |
CN107921146A (zh) * | 2015-06-23 | 2018-04-17 | 拜耳医药股份有限公司 | 纺锤体驱动蛋白(ksp)抑制剂与抗‑cd123的抗体的抗体药物缀合物(adc) |
PL3313884T3 (pl) | 2015-06-29 | 2021-05-31 | Immunogen, Inc. | Przeciwciała anty-cd123 oraz ich koniugaty i pochodne |
SG11201808167VA (en) | 2016-03-24 | 2018-10-30 | Bayer Pharma AG | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
JP7022707B2 (ja) * | 2016-06-15 | 2022-02-18 | バイエル・ファルマ・アクティエンゲゼルシャフト | Ksp阻害剤および抗cd123抗体を含む特異的抗体-薬物-コンジュゲート(adc) |
CA3037688A1 (en) | 2016-09-21 | 2018-03-29 | Aptevo Research And Development Llc | Cd123 binding proteins and related compositions and methods |
KR20190099250A (ko) | 2016-12-21 | 2019-08-26 | 바이엘 악티엔게젤샤프트 | 효소적으로 절단가능한 기를 갖는 세포독성 활성제의 전구약물 |
CA3047522A1 (en) | 2016-12-21 | 2018-06-28 | Bayer Pharma Aktiengesellschaft | Specific antibody drug conjugates (adcs) having ksp inhibitors |
MX2019007641A (es) | 2016-12-21 | 2019-09-09 | Bayer Pharma AG | Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente. |
CN111247167A (zh) | 2017-06-02 | 2020-06-05 | 辉瑞公司 | Flt3的特异性抗体及其用途 |
EP3746079A1 (en) | 2018-01-31 | 2020-12-09 | Bayer Aktiengesellschaft | Antibody drug conjugates (adcs) with nampt inhibitors |
AU2020269268A1 (en) | 2019-05-04 | 2021-11-11 | Inhibrx Biosciences, Inc. | CD123-binding polypeptides and uses thereof |
WO2021013693A1 (en) | 2019-07-23 | 2021-01-28 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (adcs) with nampt inhibitors |
WO2022144836A1 (en) | 2020-12-31 | 2022-07-07 | Sanofi | Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123 |
WO2023012367A1 (en) * | 2021-08-06 | 2023-02-09 | Universität Basel | Discernible cell surface protein variants for use in cell therapy |
EP4296280A1 (en) * | 2022-06-21 | 2023-12-27 | F. Hoffmann-La Roche AG | Cd123 and cd200 as markers for the diagnosis and immune-eradication of leukemic stem cells (lscs) |
WO2024105206A1 (en) | 2022-11-17 | 2024-05-23 | Vincerx Pharma Gmbh | Antibody-drug-conjugates cleavable in a tumor microenvironment |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
WO1994007921A1 (en) | 1992-09-25 | 1994-04-14 | Commonwealth Scientific And Industrial Research Organisation | Target binding polypeptide |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
WO1997024373A1 (en) * | 1995-12-29 | 1997-07-10 | Medvet Science Pty. Limited | Monoclonal antibody antagonists to haemopoietic growth factors |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
AU759779B2 (en) | 1997-10-31 | 2003-05-01 | Genentech Inc. | Methods and compositions comprising glycoprotein glycoforms |
DK2180007T4 (da) | 1998-04-20 | 2017-11-27 | Roche Glycart Ag | Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet |
PT1308455E (pt) | 1998-05-06 | 2006-08-31 | Genentech Inc | Composicao compreendendo anticorpos anti-her2 |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
PT1176195E (pt) | 1999-04-09 | 2013-07-18 | Kyowa Hakko Kirin Co Ltd | Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico |
US7229619B1 (en) | 2000-11-28 | 2007-06-12 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
EP2298809A3 (en) | 2001-07-12 | 2012-02-15 | FOOTE, Jefferson | Super humanized antibodies |
US20080260731A1 (en) * | 2002-03-01 | 2008-10-23 | Bernett Matthew J | Optimized antibodies that target cd19 |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
LT2380911T (lt) | 2003-11-05 | 2018-07-10 | Roche Glycart Ag | Antigeną surišančios molekulės, pasižyminčios padidintu fc receptoriaus surišimo afiniškumu ir efektoriaus funkcija |
US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
KR100627856B1 (ko) * | 2004-06-28 | 2006-09-25 | 에스케이 텔레콤주식회사 | 착신측 교환기를 이용하여 멀티미디어 링백톤 서비스를제공하는 방법 및 시스템 |
RU2412200C2 (ru) * | 2004-11-12 | 2011-02-20 | Ксенкор, Инк. | Fc-ВАРИАНТЫ С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ С FcRn |
US20070135620A1 (en) * | 2004-11-12 | 2007-06-14 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US20080206239A1 (en) | 2005-02-03 | 2008-08-28 | Antitope Limited | Human Antibodies And Proteins |
US20060263367A1 (en) | 2005-05-23 | 2006-11-23 | Fey Georg H | Bispecific antibody devoid of Fc region and method of treatment using same |
CA2619244A1 (en) | 2005-08-15 | 2007-02-22 | Arana Therapeutics Limited | Engineered antibodies with new world primate framework regions |
CA2660795C (en) | 2006-09-18 | 2014-11-18 | Xencor, Inc. | Optimized antibodies that target hm1.24 |
EP1985305A1 (en) | 2007-04-24 | 2008-10-29 | Vivalis | Duck embryonic derived stem cell lines for the production of viral vaccines |
EP1995309A1 (en) | 2007-05-21 | 2008-11-26 | Vivalis | Recombinant protein production in avian EBx® cells |
BRPI0819887A2 (pt) * | 2007-12-06 | 2017-05-23 | Csl Ltd | métodos e agentes para inibição de celulas-tronco leucêmicas, e para o tratamento de uma condição de câncer hematológico em um paciente, e, uso de uma molécula de ligação a antigeno |
WO2010036856A2 (en) * | 2008-09-26 | 2010-04-01 | Wyeth Llc | Compatible display vector systems |
US20100209341A1 (en) * | 2009-02-18 | 2010-08-19 | Csl Limited | Treatment of chronic inflammatory conditions |
CA2764432C (en) * | 2009-04-27 | 2017-10-24 | Kyowa Hakko Kirin Co., Ltd. | Interleukin-3 receptor alpha chain-binding antibody to treat leukemia |
NZ604510A (en) | 2010-08-17 | 2013-10-25 | Csl Ltd | Dilutable biocidal compositions and methods of use |
-
2011
- 2011-06-07 NZ NZ604510A patent/NZ604510A/xx unknown
- 2011-08-17 EP EP14165984.7A patent/EP2778175B1/en active Active
- 2011-08-17 PL PL11817577T patent/PL2606069T3/pl unknown
- 2011-08-17 GB GB1211289.2A patent/GB2488091B/en active Active
- 2011-08-17 WO PCT/AU2011/001056 patent/WO2012021934A1/en active Application Filing
- 2011-08-17 ES ES11817577.7T patent/ES2506340T3/es active Active
- 2011-08-17 KR KR1020137002451A patent/KR101347688B1/ko active IP Right Grant
- 2011-08-17 US US13/256,926 patent/US8569461B2/en active Active
- 2011-08-17 EP EP11817577.7A patent/EP2606069B1/en active Active
- 2011-08-17 CN CN201180036658.2A patent/CN103025761B/zh active Active
- 2011-08-17 DK DK11817577.7T patent/DK2606069T3/da active
- 2011-08-17 CA CA2805176A patent/CA2805176C/en active Active
- 2011-08-17 JP JP2013524306A patent/JP5524418B2/ja active Active
-
2013
- 2013-04-08 IL IL225631A patent/IL225631A/en active IP Right Grant
- 2013-09-24 US US14/035,805 patent/US20140086912A1/en not_active Abandoned
- 2013-12-26 JP JP2013268626A patent/JP5933517B2/ja active Active
-
2015
- 2015-04-03 US US14/678,356 patent/US10047161B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP5933517B2 (ja) | 2016-06-08 |
US20140086912A1 (en) | 2014-03-27 |
CA2805176A1 (en) | 2012-02-23 |
GB2488091A (en) | 2012-08-15 |
EP2778175A1 (en) | 2014-09-17 |
EP2606069A4 (en) | 2013-08-28 |
PL2606069T3 (pl) | 2015-01-30 |
GB2488091B (en) | 2013-05-01 |
EP2606069B1 (en) | 2014-07-16 |
US8569461B2 (en) | 2013-10-29 |
CN103025761B (zh) | 2014-07-30 |
US20150307615A1 (en) | 2015-10-29 |
IL225631A0 (en) | 2013-06-27 |
EP2778175B1 (en) | 2016-03-16 |
JP2014076062A (ja) | 2014-05-01 |
IL225631A (en) | 2017-07-31 |
WO2012021934A1 (en) | 2012-02-23 |
ES2506340T3 (es) | 2014-10-13 |
GB201211289D0 (en) | 2012-08-08 |
JP5524418B2 (ja) | 2014-06-18 |
CA2805176C (en) | 2015-09-29 |
US20130137855A1 (en) | 2013-05-30 |
KR101347688B1 (ko) | 2014-01-03 |
NZ604510A (en) | 2013-10-25 |
US10047161B2 (en) | 2018-08-14 |
EP2606069A1 (en) | 2013-06-26 |
CN103025761A (zh) | 2013-04-03 |
KR20130047736A (ko) | 2013-05-08 |
JP2013537418A (ja) | 2013-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2606069T3 (da) | Humaniserede antistoffer mod alfakæden af anti-interleukin-3-receptoren | |
LTPA2019011I1 (lt) | CGRP antikūnai | |
HRP20181360T1 (hr) | Anti-cd28 humanizirana protutijela | |
DK2521736T3 (da) | Humaniserede antistoffer | |
CY2017025I2 (el) | Αντιδοτα αντιπηκτικων | |
DK3178851T3 (da) | Anti-cd40-antistoffer | |
SMT201700083B (it) | Anticorpi monoclonali | |
BRPI0907532A2 (pt) | Anticorpos anti-c5ar humanizados | |
DK2643018T3 (da) | Anti-il-6-antistoffer til behandling af oral mucositis | |
SMT201600193B (it) | Nuovo anticorpo anti-dr5 | |
BR112013022797A2 (pt) | anticorpos anti-ctla4 humanizados | |
DK3502138T3 (da) | Tavse Fc-varianter af anti-CD40-antistoffer | |
BR112012030311A2 (pt) | anticorpo | |
CO7020871A2 (es) | Anticuerpos anti-il-36r | |
DK3741883T3 (da) | Antistofbiblioteker | |
DK3323830T3 (da) | Anti-gd2 antibodies | |
CR20170001A (es) | Anticuerpos anti factor d humanizados | |
DK2651436T3 (da) | Mycobakterie antigen sammensætning. | |
BR112013010688A2 (pt) | anticorpos anti c-met | |
BRPI0923359A2 (pt) | Anticorpos anti-igf | |
DK2766392T3 (da) | Fremgangsmåde til oprensning af antistoffer | |
DK3284754T3 (da) | Anti-cd38-antistoffer | |
DK3252076T3 (da) | Diagnostisk anvendelse af antistoffer mod ror-1-protein | |
BR112013002297A2 (pt) | anticorpos humanizados seguros e funcionais | |
CO6791565A2 (es) | Anticuerpos anti-notch1 |